Takeda Reports Positive Phase 3 Results for Arcotatug Tavatecan
Takeda said the G-HOPE-001 study showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival in previously treated advanced gastric or gastroesophageal junction cancer.